ArticleScientific reports2026
A new Epseptimavirus bacteriophage vB_SalS-SIY1lw as a potential antimicrobial alternative to multidrug-resistant Salmonella Infantis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Salmonella Infantis is an emerging pathogen highly associated with antibiotic-resistant issues and has contributed to increasing foodborne illness in recent years. Thus, finding novel antimicrobial agents is urgent for the solution. The objective was to characterize a newly isolated Epseptimavirus phage with antimicrobial activity against multidrug-resistant S. Infantis strains. Salmonella phage vB_SalS-SIY1lw (or SIY1lw) is a new member of the phages belonging to the Epseptimavirus genus. SIY1lw contained the receptor binding protein (ORF 23) and tail fiber protein (ORF 43) genes—both associated with bacterial host recognition and binding—similar to that in Salmonella phage OSY-STA (the Epseptimavirus genus) and Escherichia phage DaisyDussoix (the Tequintavirus genus), respectively. For biological traits, SIY1lw has a latent period of 30 min and an estimated burst size of 42 PFU/CFU. The phage was polyvalent against S. enterica (Infantis and Newport) and non-pathogenic E. coli strains. The in vitro antimicrobial activity test showed that the phage with MOI of 1,000 is the most effective in reducing S. Infantis FSIS7823 and FSIS4921 by 1 and 0.8 log, respectively, over the 6-h treatment at 25 °C. These findings indicate that the new Epseptimavirus phage SIY1lw has future potential to develop an antimicrobial alternative to multidrug-resistant S. Infantis strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.